Merck & Co., Inc.’s patent infringement suit against Mylan automatically stays FDA approval of Mylan’s ANDA for ezetimibe/simvastatin until May 2012 or until an adverse court decision, if any, whichever…
Merck & Co. Inc. continues to pursue a patent infringement lawsuit against Lupin Ltd.
The Company and AstraZeneca received notice in September 2009 that Lupin had filed an ANDA for esomeprazole…
A trial which had been scheduled for January 2010 with respect to the abbreviated new drug applications filed by IVAX Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories challenging Merck & Co.…
Teva Pharmaceuticals Inc. has withdrawn its appeal to a decision upholding the validity of Merck & Co. Inc.’s Singulair patent.
In February 2007, the Company received a notice from Teva Pharmaceuticals,…
Merck & Co., Inc. has appealed a decision by the European Patent Office revoking a new patent that covers the once-weekly administration of alendronate remains pending.
In September 2004, the Company…
Merck & Co. Inc. is cooperating with the U.S. Federal Trade Commission in responding to a Civil Investigative Demand regarding the settlement of the Ranbaxy patent suit.
The Company and AstraZeneca…
Merck & Co., Inc.’s patent infringement suit against Sandoz Inc. is scheduled to go to trial in December 2010.
In January 2009, the company received notice from Sandoz that it had…
Telcordia Technologies Inc.’s patent infringement suit against Tellabs, Inc., remains pending.
On May 4, 2009, Telcordia Technologies filed a complaint against Tellabs in the U.S. District Court for the District of…
Merck & Co. Inc. and Schering-Plough Corporation continue to pursue a patent infringement lawsuit against generic pharmaceutical manufacturers who filed abbreviated new drug applications for generic ezetimibe (Zetia).
An abbreviated new…
Teva Pharmaceuticals Inc. has appealed the decision upholding the validity of Merck & Co. Inc.’s Singulair patent.
On Aug. 19, 2009, the U.S. District Court for the District of New Jersey…